Evaluation of the effect of Atomoxetine on impulsive state of High impulsive Tourette’s patients.

Phase 1

• Conditions: High impulsive Tourette’s syndrome patients; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]; MedDRA version: 20.0Level: LLTClassification code 10042808Term: Syndrome Gilles de la TouretteSystem Organ Class: 100000004850

• Registration Number: EUCTR2019-004455-36-FR
• Lead Sponsor: CHU DE POITIERS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-11-26
• Last Update Posted: 25 August 2020

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Patients: Tourette’s patients from 10 to 35 years old diagnosed according to the criteria of DSM-V, with high impulsive trait, and who freely consent to this study

Healthy subjects, of normal development, free from any neuropsychiatric pathology, matched 1:1 in age and sex to the patients recruited in this study.
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Other psychiatric disease of the axis I of DSM-IV, severe depression, allergic reactions to chemical coumpounds of the treatment or medical contraindications of atomoxetine, concommitent treatments contraindicated with atomoxetine (IMAO) interrupted from less tha 2 weeks or Clonidine or Methyphenidate interrupted from less than 1 month

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified